英国白癜风疾病负担与治疗模式:全国纵向回顾研究
该研究利用英国临床实践研究数据链和医院统计数据库,回顾分析2010至2021年白癜风患者。17 239例新发患者发病率为0.16/1000人年,66 217例现患患者患病率从0.21%升至0.38%。诊断后1年内60.8%未接受白癜风相关治疗,诊断至首次治疗中位时间34.0个月。
要点
- 白癜风发病率0.16/1000人年,患病率从2010年0.21%升至2021年0.38%。
- 诊断后1年内60.8%未治疗,诊断至首次治疗中位时间34.0个月。
- 抑郁和/或焦虑终生诊断率24.6%,青少年诊断后7.4% vs 诊断前1.8%。
核心结论
- 多数白癜风患者在诊断后1年内未接受白癜风相关治疗,首次治疗时间超过2年,提示白癜风可能被忽视。
- 需要新的有效治疗、早期启动治疗及心理干预与支持以减轻白癜风负担。
研究设计与样本
- 回顾性研究,使用英国临床实践研究数据链和医院统计数据库,分析2010年1月1日至2021年12月31日白癜风患者。
- 纳入17 239例新发患者和66 217例现患患者。
主要发现
- 新发患者平均发病率0.16/1000人年(范围0.10至0.19),现患患者患病率从0.21%(2010年)升至0.38%(2021年)。
- 诊断后最常见合并症为糖尿病(19.4%)、湿疹(8.9%)、甲状腺疾病(7.5%)和类风湿关节炎(6.9%)。
- 任何时间记录的精神健康诊断包括抑郁和/或焦虑(24.6%)、抑郁(18.5%)、焦虑(16.0%)和睡眠障碍(12.7%)。
- 诊断后记录抑郁和/或焦虑在White患者为29.0%,Black患者18.8%,Asian患者16.1%。
- 青少年诊断后抑郁和/或焦虑诊断(7.4%)多于诊断前(1.8%)。
关键数值与推荐
- 诊断后第一年医疗资源使用最频繁:皮肤科相关门诊101.9/100人年,全科医生咨询97.9/100人年。
- 诊断后第一年60.8%新发患者未接受白癜风相关治疗(外用糖皮质激素、外用钙调神经磷酸酶抑制剂、口服糖皮质激素或光疗),第二年增至82.0%。
- 诊断至首次治疗中位时间34.0个月(95%CI 31.6-36.4)。
- 诊断后第一年16.7%新发患者记录使用抗抑郁药和/或抗焦虑药。
- 2019年85.0%现患患者未接受白癜风相关治疗。
临床怎么用
- 临床应关注白癜风患者诊断后早期治疗启动,避免延误。
- 对白癜风患者应常规筛查抑郁、焦虑和睡眠障碍,尤其青少年和White患者。
- 全科和皮肤科门诊是白癜风患者主要就诊途径,需加强疾病重视和教育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: UK studies examining vitiligo burden and vitiligo-related healthcare resource utilization (HCRU) are lacking. OBJECTIVE: To describe the incidence and prevalence of vitiligo, the demographic and clinical characteristics of patients with vitiligo, vitiligo burden, HCRU, incidence of mental health comorbidities and management strategies, including treatment patterns. METHODS: This retrospective study used UK Clinical Practice Research Datalink and Hospital Episode Statistics databases to analyse patients with vitiligo from 1 January 2010 to 31 December 2021. RESULTS: Among 17 239 incident patients, mean incidence of vitiligo was 0.16 (2010-2021) per 1000 person-years [PY; range 0.10 (2020-COVID-19) to 0.19 (2010/2013/2018)]; among 66 217 prevalent patients, prevalence increased from 0.21% (2010) to 0.38% (2021). The most common comorbidities recorded after vitiligo diagnosis were diabetes (19.4%), eczema (8.9%), thyroid disease (7.5%) and rheumatoid arthritis (6.9%). Mental health diagnoses recorded at any time included depression and/or anxiety (24.6%), depression (18.5%), anxiety (16.0%) and sleep disturbance (12.7%), and recorded after vitiligo diagnosis in 6.4%, 4.4%, 5.5% and 3.9%, respectively. Mental health comorbidities were more common in White (e.g. depression and/or anxiety 29.0%) than in Black (18.8%) and Asian (16.1%) patients. In adolescents, depression and/or anxiety was most commonly diagnosed after a vitiligo diagnosis than before (7.4% vs. 1.8%). Healthcare resources were used most frequently in the first year after vitiligo diagnosis (incident cohort), typically dermatology-related outpatient appointments (101.9/100 PY) and general practitioner consultations (97.9/100 PY). In the year after diagnosis, 60.8% of incident patients did not receive vitiligo-related treatment (i.e. topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids or phototherapy), increasing to 82.0% the next year; median time from diagnosis to first treatment was 34.0 months (95% confidence interval 31.6-36.4). Antidepressants and/or anxiolytics were recorded for 16.7% of incident patients in the year after diagnosis. In 2019, 85.0% of prevalent patients did not receive vitiligo-related treatments. CONCLUSION: Most patients were not on vitiligo-related treatments within a year of diagnosis, with the time to first treatment exceeding 2 years, suggesting that vitiligo may be dismissed as unimportant. New effective treatments, early initiation and psychological intervention and support are needed to reduce the vitiligo burden on patients. Vitiligo is a chronic disease in which cells that produce the skin pigment called melanin are attacked, resulting in white or pale patches of skin. It is diagnosed in an estimated 0.2–0.8% of people in Europe. This study aimed to describe how many new cases of vitiligo were recorded between 2010 and 2021 in the UK and the overall percentage of people with vitiligo. Linked national general practitioner (GP) and hospital-based records containing information on medical diagnoses, admissions and hospital visits were used. Records of other diseases and conditions, including mental health conditions, in combination with healthcare service use and treatment prescribed to patients with vitiligo, were studied to describe the impact of living with vitiligo. It was found that 0.16 new cases of vitiligo were recorded per 1000 person-years (for example, 0.16 new cases would have been recorded if 1000 people were followed for 1 year or if 100 people were all followed for 10 years) between 2010 and 2021. In 2021, 0.4% of the population studied had vitiligo. In the 5 years after a new diagnosis of vitiligo, the most common other diseases recorded were diabetes (19%), eczema (9%), thyroid disease (8%) and rheumatoid arthritis (7%), and the most common mental health conditions were depression and/or anxiety (25%). In the year after diagnosis, GP and dermatology outpatient visits were the most common type of medical services used. In 2019, 85% of all individuals with vitiligo were not receiving any vitiligo-related treatment (such as creams or phototherapy). It took approximately 34 months from diagnosis of vitiligo to the start of first treatment. The results suggest that new effective treatments and psychological interventions are needed to reduce the burden of vitiligo.
引用
- Eleftheriadou V, Delattre C, Chetty-Mhlanga S, et al. Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK. Br J Dermatol. 2024. PMID: 38534198. doi:10.1093/bjd/ljae133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。